Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
Charles River Laboratories International Inc. has announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. under which Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
Charles River to Perform Plasmid Production for Ship of Theseus
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
Charles River and Navega Announce Gene Therapy Manufacturing Collaboration
DURECT and Charles River Enter into Collaboration Agreement for ALZET
Wheeler Bio Seals Agreement with Charles River